# The Women TAF-FTC Benchmark Study

> **NCT05140954** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Washington** · enrollment: 54 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** co-formulated 25mg TAF/ 200mg FTC

## Key facts

- **NCT ID:** NCT05140954
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140954, "The Women TAF-FTC Benchmark Study". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05140954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*